New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Friday, Nov 20, 2026
Export BMY’s income statement to Excel — free account
Bristol Myers Squibb Company
BMYHealthcare Drug Manufacturers General
Bristol Myers Squibb Company’s revenue for fiscal 2025 (year ended December 2025) was $48.2 billion, roughly unchanged from fiscal 2024.
- Revenue
- +6.93%
- EPS
- −2.78%
- Free cash flow
- −36.0%
- Total debt
- −12.5%
Quarter to September 2026, against a year earlier
59.43
1.09
+1.87%
Follow BMY
Alert me
Revenue to profit Q3 FY2026, quarter to Sep 30, 2026
Of every $100 of revenue, $16.54 was left as profit. What is an income statement?
| Revenue | 13.1 | 100.0% |
|---|---|---|
| Cost of revenue | −4.1 | −31.7% |
| Gross profit | 8.9 | 68.3% |
| Research & development | −2.4 | −18.1% |
| Selling, general & admin | −1.7 | −13.0% |
| Other operating costs | −2.3 | −17.8% |
| Operating income | 2.5 | 19.4% |
| Income tax | −0.4 | −2.9% |
| Net income | 2.2 | 16.5% |
Net margin (right axis)
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| Revenue | $12.5B | $11.5B | $13.0B | $13.1B |
| Operating income | $1.5B | $3.2B | $4.1B | $2.5B |
| Net income | $1.1B | $2.7B | $3.3B | $2.2B |
| Net margin (right axis) | 8.7% | 23.3% | 25.6% | 16.5% |
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
Revenue |
+8 more quarters Free account |
12,502.00 | 11,489.00 | 12,973.00 | 13,069.00 |
Revenue Growth |
1.30% | 2.57% | 5.74% | 6.93% | |
Cost of Revenue |
4,096.00 | 3,421.00 | 3,726.00 | 4,146.00 | |
Gross Profit |
8,406.00 | 8,068.00 | 9,247.00 | 8,923.00 | |
R&D Expenses |
2,586.00 | 2,649.00 | 2,959.00 | 2,365.00 | |
SG&A Expenses |
2,181.00 | 1,617.00 | 1,826.00 | 1,699.00 | |
Operating Income |
1,472.00 | 3,239.00 | 4,086.00 | 2,536.00 | |
| 1,470.00 | 3,240.00 | 4,086.00 | 2,536.00 | ||
Income Tax Provision |
384.00 | 561.00 | 770.00 | 374.00 | |
Income after Tax |
1,086.00 | 2,679.00 | 3,316.00 | 2,162.00 | |
Non-Controlling Interest |
(1.00) | 1.00 | (1.00) | 0.00 | |
Net Income Common |
1,087.00 | 2,677.00 | 3,317.00 | 2,162.00 | |
EPS (Basic) |
0.53 | 1.31 | 1.62 | 1.06 | |
EPS (Diluted) |
0.53 | 1.31 | 1.62 | 1.05 | |
Shares (Basic, Weighted) |
2,034.00 | 2,038.00 | 2,042.00 | 2,043.00 | |
Shares (Diluted, Weighted) |
2,039.00 | 2,047.00 | 2,048.00 | 2,053.00 | |
Gross Margin |
67.24% | 70.22% | 71.28% | 68.28% | |
EBIT Margin |
11.77% | 28.19% | 31.50% | 19.40% | |
EBT margin |
11.76% | 28.20% | 31.50% | 19.40% | |
Net Profit Margin |
8.69% | 23.30% | 25.57% | 16.54% | |
EBITDA |
2,449.00 | 3,833.00 | 4,680.00 | 3,162.00 | |
EBIT |
1,472.00 | 3,239.00 | 4,086.00 | 2,536.00 | |
Income from Continuous Operations |
1,086.00 | 2,679.00 | 3,316.00 | 2,162.00 | |
Consolidated Net Income/Loss |
1,086.00 | 2,678.00 | 3,316.00 | 2,162.00 | |
EPS (Basic, from Continuous Ops) |
0.53 | 1.31 | 1.62 | 1.06 | |
EPS (Diluted, from Cont. Ops) |
0.53 | 1.31 | 1.62 | 1.05 | |
EPS (Basic, Consolidated) |
0.53 | 1.31 | 1.62 | 1.06 | |
EPS (Diluted, Consolidated) |
0.53 | 1.31 | 1.62 | 1.05 | |
Shares (Diluted, Average) |
2,041.00 | 2,047.00 | 2,048.00 | 2,053.00 | |
EBITDA Margin |
19.59% | 33.36% | 36.07% | 24.19% | |
Operating Cash Flow Margin |
15.79% | 9.61% | 26.15% | 31.99% |
In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 18, 2026